Quantisnow Logo
Dashboard

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

$KROS
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $KROS alert in real time by email

LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate at the following healthcare conferences:

TD Cowen 45th Annual Healthcare Conference

Leerink Partners Global Healthcare Conference

For each presentation, an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of each event.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. One of Keros' product candidates, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros' second product candidate, KER-065, is being developed for the treatment of neuromuscular diseases. Keros' most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.

Investor Contact:

Justin Frantz

jfrantz@kerostx.com    

617-221-6042    



Primary Logo

Get the next $KROS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$KROS

DatePrice TargetRatingAnalyst
1/21/2025Overweight → Neutral
Cantor Fitzgerald
1/17/2025$15.00Outperform → Neutral
Wedbush
12/16/2024$102.00 → $63.00Outperform
Oppenheimer
12/16/2024Buy → Neutral
Guggenheim
12/13/2024$100.00 → $47.00Buy
H.C. Wainwright
12/12/2024Buy → Hold
TD Cowen
12/12/2024Outperform → Mkt Perform
William Blair
12/12/2024Buy → Neutral
BTIG Research
More analyst ratings

$KROS
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Keros Therapeutics Announces Review of Strategic Alternatives

    Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that its Board of Directors (the "Board") has determined to initiate a formal review process to evaluate strategic alternatives to maximize stockholder value for the Company. In connection with this determination, th

    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

    Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, together with preclinical data, support the therapeutic potential of KER-065 for broad impact in Duchenne muscular dystrophy ("DMD") and other neuromuscular indicationsKeros plans on advancing KER-065 into a Phase 2 clinical trial in DMD, subject to positive regulatory interactionKeros to host a conference call and webcast today, March 31, 2025, at 8:00 a.m. ET LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutic

    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

    LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate at the following healthcare conferences: TD Cowen 45th Annual Healthcare Conference Date and Time: Monday, March 3, 2025 at 9:50 a.m. Eastern timeLink: https://wsw.com/webcast/cowen177/kros/2049093Format: Fireside Chat Presen

    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$KROS
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$KROS
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$KROS
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$KROS
 SEC Filings

See more

$KROS
 Leadership Updates

Live Leadership Updates

See more

  • Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

    LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November 1, 2024. "We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs," said Chair and Chi

    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

    LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024. "On behalf of the Board, we are delighted to welcome Jean-Jacques to Keros during this pivotal phase of our growth," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "Jean-Jacques is a deeply

    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors

    LEXINGTON, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it appointed Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. "Dr. Seth's deep industry experience and expertise in drug development, global operations and product launches will be an invaluable addition to our Board of Directors," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "We a

    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$KROS
 Financials

Live finance-specific insights

See more

  • Keros Therapeutics Announces Review of Strategic Alternatives

    Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that its Board of Directors (the "Board") has determined to initiate a formal review process to evaluate strategic alternatives to maximize stockholder value for the Company. In connection with this determination, th

    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

    Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, together with preclinical data, support the therapeutic potential of KER-065 for broad impact in Duchenne muscular dystrophy ("DMD") and other neuromuscular indicationsKeros plans on advancing KER-065 into a Phase 2 clinical trial in DMD, subject to positive regulatory interactionKeros to host a conference call and webcast today, March 31, 2025, at 8:00 a.m. ET LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutic

    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

    LEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2024. "The efforts over the past year by the team at Keros have positioned us to continue to advance our promising pipeline of novel therapeutics," said Jasbir S. Seehra, Ph.D., Chair and Chief

    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$KROS
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more